TRIM31 and metabolic dysfunction-associated steatohepatitis: Consistent with the data in Fig. 8, AAV8-mediated Trim31 gene therapy significantly protects against HFHF-induced nonalcoholic steatohepatitis (NASH) in vivo (Supplementary Fig. 18a–j).